Related Experiment Video
Updated: Dec 28, 2025
08:13
Mitigation of Blood Borne Cell Attachment to Metal Implants through CD47-Derived Peptide Immobilization
Published on: December 3, 2020
4.9K
A novel biofunctionalizing peptide for metallic alloy.
Akane Sakaguchi-Mikami1,2, Kazuhiro Fujimoto3, Tetsushi Taguchi4
1Department of Medical technology, School of Health sciences, Tokyo University of Technology, 5-23-22 Nishi-Kamata, Ohta, Tokyo, 144-8535, Japan. amikami@stf.teu.ac.jp.
Biotechnology Letters
|February 11, 2020
Summary
Researchers developed a novel peptide (SBP-A) to improve the biocompatibility of SUS316L stainless steel. This peptide enhances endothelial cell adhesion, offering a promising strategy for advanced medical implants and reducing implant-associated diseases.
Area of Science:
- Biomaterials Science
- Surface Chemistry
- Biotechnology
Background:
- Metallic alloys like SUS316L are crucial for medical implants but can cause adverse reactions such as stent thrombosis.
- Improving the biocompatibility of metallic biomaterials is essential for preventing implant-associated diseases.
Purpose of the Study:
- To develop a simple and efficient method for biofunctionalizing SUS316L stainless steel surfaces.
- To isolate a peptide that specifically binds to SUS316L for enhanced biomaterial surface modification.
Main Methods:
- Phage panning was employed to identify peptides with binding affinity to SUS316L stainless steel.
- The identified SUS316L-binding peptide (SBP-A) was used to immobilize anti-ICAM antibodies.
- The biofunctionalized surface was evaluated for its interaction with vascular endothelial cells and smooth muscle cells.
Main Results:
- A 12-mer peptide, SBP-A (VQHNTKYSVVIR), was identified as a SUS316L-binding peptide.
- SBP-A demonstrated stable binding to SUS316L surfaces and showed no toxicity to human umbilical vein endothelial cells (HUVECs).
- The SBP-A-modified surface successfully promoted the immobilization of vascular endothelial cells, indicating effective biofunctionalization.
Conclusions:
- The novel peptide SBP-A enables effective biofunctionalization of SUS316L surfaces, presenting a potential interface molecule for stent modification.
- This peptide-based approach represents a novel strategy for surface functionalization to promote endothelialization.
- The developed procedure offers a simple and efficient method for creating biocompatible materials.
